 NEW HAVEN, Conn., May 20, 2022 GLOBE NEWSWIRE -- BioXcel Therapeutics, Inc. Nasdaq: BTAI, a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference now scheduled for Tuesday, May 24 at 9:00 a.m. ET. Dr. Mehta will discuss the Companys neuroscience and immuno-oncology programs as well as its artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process. He will also discuss the Companys commercial and launch readiness plans for IGALMITM dexmedetomidine sublingual film. 